Published in Toxicol In Vitro on January 31, 2012
Real-time cell analysis: sensitivity of different vertebrate cell cultures to copper sulfate measured by xCELLigence(®). Ecotoxicology (2014) 0.80
A bioactive probe for glutathione-dependent antioxidant capacity in breast cancer patients: implications in measuring biological effects of arsenic compounds. J Pharmacol Toxicol Methods (2013) 0.79
A bioactive probe of the oxidative pentose phosphate cycle: novel strategy to reverse radioresistance in glucose deprived human colon cancer cells. Toxicol In Vitro (2012) 0.79
Berberine activates AMPK to suppress proteolytic processing, nuclear translocation and target DNA binding of SREBP-1c in 3T3-L1 adipocytes. Mol Med Rep (2017) 0.75
Antimetabolite TTL-315 selectively kills glucose-deprived cancer cells and enhances responses to cytotoxic chemotherapy in preclinical models of cancer. Oncotarget (2016) 0.75
A calpain inhibitor protects against fractalkine production in lipopolysaccharide-treated endothelial cells. Kidney Res Clin Pract (2017) 0.75
Clonogenic assay of cells in vitro. Nat Protoc (2006) 11.85
Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem (2000) 8.76
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res (1988) 8.53
Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev (2007) 6.91
Trends in oxidative aging theories. Free Radic Biol Med (2007) 4.51
A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer (1987) 3.62
Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer (1998) 2.95
Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res (1991) 2.06
Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J Clin Microbiol (2003) 1.90
Hydrogen peroxide as a cell-survival signaling molecule. Antioxid Redox Signal (2009) 1.63
Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res (2003) 1.56
The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res (2004) 1.49
Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci U S A (2000) 1.40
Application and evaluation of the alamarBlue assay for cell growth and survival of fibroblasts. In Vitro Cell Dev Biol Anim (1998) 1.33
Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol (2008) 1.33
Detection of reactive oxygen species via endogenous oxidative pentose phosphate cycle activity in response to oxygen concentration: implications for the mechanism of HIF-1alpha stabilization under moderate hypoxia. J Biol Chem (2007) 1.21
The differential effects of dithiothreitol and 2-mercaptoethanol on the secretion of partially and completely assembled immunoglobulins suggest that thiol-mediated retention does not take place in or beyond the Golgi. Mol Biol Cell (1994) 1.18
G6PD deficient cells and the bioreduction of disulfides: effects of DHEA, GSH depletion and phenylarsine oxide. Biochem Biophys Res Commun (2000) 1.14
Selenium and the thioredoxin and glutaredoxin systems. Biomed Environ Sci (1997) 1.10
The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther (2001) 1.08
Targeting tumors with hypoxia-activated cytotoxins. Front Biosci (2007) 1.07
Phenazine ethosulfate as a preferred electron acceptor to phenazine methosulfate in dye-linked enzyme assays. Anal Biochem (1979) 1.05
Serum albumin leads to false-positive results in the XTT and the MTT assay. Biotechniques (2007) 1.05
A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol (2010) 1.02
Modification of MTT assay conditions to examine the cytotoxic effects of amitraz on the human lymphoblastoid cell line, WIL2NS. Toxicol In Vitro (2005) 1.00
On the mechanism of production of superoxide radical by reaction mixtures containing NADH, phenazine methosulfate, and nitroblue tetrazolium. Arch Biochem Biophys (1984) 0.98
Mutation in the glucose-6-phosphate dehydrogenase gene leads to inactivation of Ku DNA end binding during oxidative stress. J Biol Chem (2002) 0.96
Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol (1996) 0.94
PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation. Leukemia (2004) 0.94
Radiation response of cells during altered protein thiol redox. Radiat Res (2003) 0.92
Evaluation of viability and proliferative activity of human urothelial cells cultured onto xenogenic tissue-engineered extracellular matrices. Urology (2011) 0.89
Reduction of 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt (XTT) is dependent on CaFRE10 ferric reductase for Candida albicans grown in unbuffered media. Microbiology (2006) 0.88
Oxidation of cellular thiols by hydroxyethyldisulphide inhibits DNA double-strand-break rejoining in G6PD deficient mammalian cells. Int J Radiat Biol (2000) 0.87
The modified high-density survival assay is the useful tool to predict the effectiveness of fractionated radiation exposure. J Radiat Res (2010) 0.87
Mutation in G6PD gene leads to loss of cellular control of protein glutathionylation: mechanism and implication. J Cell Biochem (2008) 0.86
Assay conditions can influence the outcome of cytotoxicity tests of nanomaterials: better assay characterization is needed to compare studies. Toxicol In Vitro (2009) 0.85
Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines. Neoplasia (2009) 0.85
Role of vicinal protein thiols in radiation and cytotoxic responses. Radiat Res (2006) 0.83
Effect of 2-mercaptoethanol on glutathione levels, cystine uptake and insulin secretion in insulin-secreting cells. Eur J Biochem (1992) 0.82
Cell density dependent plating efficiency affects outcome and interpretation of colony forming assays. Radiother Oncol (1996) 0.82
Pharmacodynamics and long-term toxicity of etoposide. Cancer Chemother Pharmacol (1994) 0.81
Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer. Oncol Rep (2008) 0.81
Development of an XTT tetrazolium salt-based assay for detection of specific hyperthermia sensitizers in a high-flux screening programme. Int J Hyperthermia (2002) 0.81
Counting clonogenic assays from normoxic and anoxic irradiation experiments manually or by using densitometric software. Phys Med Biol (2010) 0.79
Combination toxicity of etoposide (VP-16) and photosensitisation with a water-soluble aluminium phthalocyanine in K562 human leukaemic cells. Br J Cancer (1996) 0.79
Reactive oxygen species involved in phenazine-methosulfate-induced rat lens opacification. An experimental model of cataract. Ophthalmic Res (1994) 0.77
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med (2005) 4.92
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res (2007) 3.44
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res (2007) 2.78
IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov (2012) 2.56
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev (2008) 2.47
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A (2008) 2.18
RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Dev Cell (2004) 2.13
Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets (2007) 1.86
Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis (2011) 1.86
Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem (2006) 1.81
RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev (2003) 1.48
Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biol Ther (2003) 1.46
Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci (2012) 1.40
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology (2012) 1.37
Cyclin D1 functions in cell migration. Cell Cycle (2006) 1.36
The crystal structure of the BAR domain from human Bin1/amphiphysin II and its implications for molecular recognition. Biochemistry (2006) 1.35
The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol (2009) 1.34
Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. Mol Cell Biol (2003) 1.26
Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. J Biol Chem (2008) 1.25
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol (2010) 1.22
Detection of reactive oxygen species via endogenous oxidative pentose phosphate cycle activity in response to oxygen concentration: implications for the mechanism of HIF-1alpha stabilization under moderate hypoxia. J Biol Chem (2007) 1.21
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem (2008) 1.18
Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther (2002) 1.18
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev (2012) 1.16
Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg (2009) 1.11
Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res (2007) 1.10
Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem (2008) 1.07
Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res (2010) 1.06
Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother (2010) 1.04
Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res (2005) 1.04
Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets (2005) 1.02
RhoB regulates PDGFR-beta trafficking and signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2007) 1.02
Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res (2012) 1.01
Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin Cancer Res (2003) 1.00
Cancer: Why tumours eat tryptophan. Nature (2011) 0.99
Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res (2011) 0.97
Reduction of hepatitis C virus NS5A phosphorylation through its interaction with amphiphysin II. Biochem Biophys Res Commun (2005) 0.96
Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene (2003) 0.96
AACR Cancer Progress Report 2013. Clin Cancer Res (2013) 0.95
Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Mol Cancer Ther (2010) 0.94
Bin3 deletion causes cataracts and increased susceptibility to lymphoma during aging. Cancer Res (2008) 0.93
A role for RhoB in synaptic plasticity and the regulation of neuronal morphology. J Neurosci (2010) 0.93
Radiation response of cells during altered protein thiol redox. Radiat Res (2003) 0.92
Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy (2010) 0.91
RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac. J Cell Biochem (2011) 0.90
The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J Immunol (2014) 0.89
Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther (2011) 0.89
China's new rural cooperative medical scheme and underutilization of medical care among adults over 45: evidence from CHARLS pilot data. J Rural Health (2013) 0.89
Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res (2002) 0.89
Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J Cell Biochem (2003) 0.89
Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res (2007) 0.89
CONCURRENT WHOLE BRAIN RADIOTHERAPY AND SHORT-COURSE CHLOROQUINE IN PATIENTS WITH BRAIN METASTASES: A PILOT TRIAL. J Radiat Oncol (2013) 0.88
Bin1 attenuation in breast cancer is correlated to nodal metastasis and reduced survival. Cancer Biol Ther (2007) 0.86
RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis. Cancer Res (2012) 0.85
RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription. Nat Commun (2013) 0.84
hob1+, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress. Oncogene (2003) 0.83
Role of vicinal protein thiols in radiation and cytotoxic responses. Radiat Res (2006) 0.83
Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition. Cancer Res (2004) 0.83
Genetic response to DNA damage: proapoptotic targets of RhoB include modules for p53 response and susceptibility to Alzheimer's disease. Cancer Biol Ther (2005) 0.82
Genomic profiling of miRNAs in two human lens cell lines. Curr Eye Res (2010) 0.82
Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene (2003) 0.82
The N-BAR domain protein, Bin3, regulates Rac1- and Cdc42-dependent processes in myogenesis. Dev Biol (2013) 0.82
The Interaction Between an Individual's Acculturation and Community Factors on Physical Inactivity and Obesity: A Multilevel Analysis. Am J Public Health (2015) 0.81
Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biol Ther (2004) 0.81
Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice. PLoS One (2009) 0.81
Glucose deprivation increases nuclear DNA repair protein Ku and resistance to radiation induced oxidative stress in human cancer cells. Cell Biochem Funct (2009) 0.81
mDia function is critical for the cell suicide program triggered by farnesyl transferase inhibition. Cancer Biol Ther (2007) 0.80
A bioactive probe of the oxidative pentose phosphate cycle: novel strategy to reverse radioresistance in glucose deprived human colon cancer cells. Toxicol In Vitro (2012) 0.79
Altered apoptotic responses in neurons lacking RhoB GTPase. Eur J Neurosci (2011) 0.79
Tissue inhibitor of metalloproteinase-4 is elevated in early-stage breast cancers with accelerated progression and poor clinical course. Am J Pathol (2009) 0.79
RhoB loss prevents streptozotocin-induced diabetes and ameliorates diabetic complications in mice. Am J Pathol (2010) 0.79
Bin1 interacts with and restrains the DNA end-binding protein complex Ku. Cell Cycle (2007) 0.78
RIN3 is a negative regulator of mast cell responses to SCF. PLoS One (2012) 0.78
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. Mol Cancer Ther (2011) 0.78
1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis. Autoimmunity (2014) 0.77
Perspectives on emerging trends in cancer research. Cancer Res (2011) 0.76
Development of polyamine transport ligands with improved metabolic stability and selectivity against specific human cancers. J Med Chem (2013) 0.76
Specific in situ detection of murine indoleamine 2, 3-dioxygenase. J Cell Biochem (2014) 0.76
Bin1 homolog hob1 supports a Rad6-Set1 pathway of transcriptional repression in fission yeast. Cell Cycle (2007) 0.75
In their own words: interviews with Cell Cycle. Cell Cycle (2010) 0.75
17: REDUCED MITOCHONDRIAL MASS UNDERLAYS DECREASED RESPIRATION IN SEPTIC IMMUNE CELLS. Crit Care Med (2016) 0.75
Cancer Research: 75th Anniversary of the Field's Most Highly Cited Basic Science Journal. Cancer Res (2016) 0.75
Development of a monoclonal antibody that specifically detects tissue inhibitor of metalloproteinase-4 (TIMP-4) in formalin-fixed, paraffin-embedded human tissues. J Cell Biochem (2010) 0.75
A perspective on cancer as an abortive autoimmune response to altered-self. Cancer Res (2015) 0.75
Meditation and blood pressure: a meta-analysis of randomized clinical trials. J Hypertens (2016) 0.75